Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 73 Roma 52 Rozzano 26 Florence 24 Ancona 24
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS San Raffaele160 AstraZeneca138 Merck Sharp & Dohme LLC98 Hoffmann-La Roche81 Novartis Pharmaceuticals73 Clear sponsor filter
Site location
Milan73 Roma52 Rozzano26 Florence24 Ancona24
All 66 locations
Target enrolment
to

Trials with a site in Milan

73 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Milan, Roma
2026-06-08
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Milan, Roma
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1
24
Milan, Candiolo
2026-05-19
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Bologna, Brescia, Milan
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Florence, Milan, Roma
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Ancona, Cona, Milan, Rozzano
2026-03-09
Recruiting
Novartis Pharmaceuticals
Observational
50
Alessandria, Avellino, Brescia, Florence, Genova, Milan, Palermo, Roma
2026-01-13
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Milan
2025-12-29
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Cona, Milan, Naples
2025-12-05
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Milan, Padova, Orbassano
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bergamo, Foggia, Genova, Milan, Pavia, Roma
2025-06-23
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Cona, Genova, Milan, Rozzano, Pisa, Roma
2025-05-30
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Ancona, Caserta, Grosseto, Milan, Rozzano, Perugia, Pordenone, Salerno
2025-04-30
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Milan, Modena
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Genova, Milan
2025-02-24
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Ancona, Brescia, Monza, Milan, Rozzano, Verona
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Genova, Milan
2024-12-12
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Milan, Roma, Torino, Verona
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Ancona, Bergamo, Brescia, Genova, Milan, Pescara, Perugia, Pisa
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Milan, Modena, Pisa, Torino
2024-10-17
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Milan, Reggio Emilia
2024-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Ancona, Milan, Rozzano, Modena, Palermo, Pavia, Roma, Verona
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alessandria, Ancona, Genova, Milan, Rozzano, Pescara, Pisa, Pavia
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Bologna, Florence, Genova, Milan, Palermo, Roma, Orbassano
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Milan, Perugia
2024-06-28
Active, closed
Novartis Pharmaceuticals
Phase 2
23
Milan, Naples
2024-04-04
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Ranica, Milan, Roma
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
49
Genova, Milan, Roma, Naples
2024-01-03
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Ancona, Milan, Rozzano
2023-12-07
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Bologna, Milan, Roma, Torino, Naples
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Milan, Rozzano, Modena, Roma, Siena
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Ancona, Milan, Salerno, Naples
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Bari, Ranica, Brescia, Milan, Roma, Torino, Naples
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Bologna, Milan, San Giovanni Rotondo
2023-08-25
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Milan, Rozzano
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Brescia, Florence, Genova, Milan, Roma
2023-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Milan, Modena, Roma
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Milan, Bassano del Grappa, Novara
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Ancona, Milan
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Meldola, Milan, Pisa, Roma, Torino
2022-11-21
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Milan, Modena
2022-10-26
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Milan
2022-10-24
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Milan, Roma, Naples
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Ancona, Milan, Salerno, Udine, Naples
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Milan, Rozzano, Torino
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Bari, Bergamo, Bologna, Florence, Genova, Milan, Rozzano, Palermo
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Milan, Roma, Verona, Novara
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Bologna, Brescia, Cona, Florence, Grosseto, Pozzilli, Milan, Rozzano
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 1
137
Milan, Rozzano
2021-10-21
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bologna, Milan, Reggio Emilia, Roma, Verona
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Meldola, Milan, Naples, Reggio Emilia
2021-07-30
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Ranica, Milan, Roma
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Ascoli Piceno, Avellino, Florence, Milan, Roma, Torino, Bassano del Grappa
2021-07-27
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Bergamo, Bologna, Brescia, Ferrara, Florence, Meldola, Milan, Monza
2021-04-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Brescia, Milan
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Milan, Genova, Naples, Pavia
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Milan, Naples
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Florence, Genova, Milan, Roma, Torino
2019-11-04
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Milan, Rozzano, Modena, Aviano, Siena, Naples
2019-10-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bologna, Milan, Roma, Rozzano
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
254
Genova, Milan, Verona, Naples
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Bergamo, Milan, Rozzano
2019-06-26
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Ancona, Bergamo, Bologna, Misterbianco, Milan, Rozzano, Palermo, Aviano
2018-12-07
Active, closed
Novartis Pharmaceuticals
Phase 1
105
Ancona, Milan, Rozzano
2018-01-29
Active, closed
Novartis Pharmaceuticals
Phase 2
29
Milan, Perugia
2017-07-04
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Bergamo, Bologna, Brescia, Meldola, Monza, Milan, Rozzano, Modena
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Bologna, Monza, Milan, Rozzano, Roma
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Milan, Modena
2015-05-27
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Ancona, Bari, Bologna, Brescia, San Giovanni Rotondo, Florence, Milan, Rozzano
2015-03-05
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Bari, Montichiari, Catania, Milan, Cefalù, Roma, Gallarate
2013-07-26
Rows per page Showing 1–73 of 73
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 73 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

27 of the 73 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 46 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 73 studies
PhaseStudiesRecruitingShare
Phase 3331245.2%
Phase 214419.2%
Phase 1/212616.4%
Phase 18211%
Phase 4415.5%
Observational111.4%
Phase 2/3111.4%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals7327
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.